Agilent Announces Acquisition of e-MSion, Early-Stage Company Behind ECD Technology that Helps Accelerate Drug Development
Agilent Technologies Inc. (NYSE: A) has acquired e-MSion, enhancing access to its innovative electron capture dissociation (ECD) technology, the ExD cell, for biopharma researchers globally. This compact device improves the assessment of complex biomolecules, allowing for faster therapeutic development. Agilent aims to integrate the ExD cell into its existing workflows and increase the reach of this technology, which enhances characterization of larger proteins. The acquisition aligns with Agilent's strategy to grow its biopharma solutions, which generated $6.85 billion in revenue for fiscal 2022.
- Acquisition of e-MSion enhances Agilent's biopharma capabilities.
- Integration of ExD cell technology allows for faster therapeutic development.
- Broader accessibility of advanced characterization technology for researchers.
- None.
Acquisition will make electron capture dissociation (ECD) technology available to more biopharma researchers and labs globally
The ExD cell is a compact device for mass spectrometers that enables biological researchers to develop biotherapeutic products more quickly to treat disease. This is done by more comprehensively and precisely breaking the chemical bonds of complex biomolecules, enabling more complete, accurate, and detailed structural information to be obtained from them.
“The talented team at e-MSion has created an important technology in accelerating biopharma development,” said
The ExD cell is compatible with instruments common in many labs, such as Agilent’s 6500 LC/Q-TOF series, which will make this powerful characterization technology—previously limited to only a few high-end mass spectrometers—more accessible to a larger share of labs and biopharma researchers worldwide.
In more technical terms, the ExD cell enables electron capture dissociation (ECD) and other modes of electron-induced fragmentation in benchtop mass spectrometers. Because of its superior characterization of larger proteins, protein fragments, and their amino-acid modifications, ECD is preferred over other dissociation techniques including collision-induced dissociation (CID), which is the dominant methodology used today.
Agilent has worked closely with e-MSion for several years and has offered the company’s ExD cell technology with its 6500 series since 2019. e-MSion was founded by
“Joining Agilent will enable seamless integration of innovative e-MSion ExD technology, data analysis, and visualization tools with Agilent’s powerful LC-QTOF instrumentation to more completely analyze macromolecules and to accelerate biopharma therapeutic discovery and development,” said
The acquisition complements Agilent’s growing biopharma solutions, including new oligonucleotide analysis software for biopharma research, broader offerings for GPC/
About
Forward Looking Statements
This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, statements regarding the capabilities the manufacturing capacity expansion brings and the assets’ future uses. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent’s customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; and customer purchasing decisions and timing. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that its cost-cutting initiatives will impair its ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of its supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; the adverse impacts of and risks posed by the COVID-19 pandemic; and other risks detailed in Agilent’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005669/en/
+1 669 255 7696
sarah.litton@agilent.com
Source:
FAQ
What is Agilent Technologies' latest acquisition?
How does the ExD cell technology benefit biopharma researchers?
What does the acquisition of e-MSion mean for Agilent's business strategy?
What are the expected impacts of the ExD cell integration?
